Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The authors compared medication-induced mood switch risk (primary outcome), as well as treatment response and side effects (secondary outcomes) with three acute-phase treatments for bipolar II depression. METHOD: In a 16-week, double-blind, multisite comparison study, 142 participants with bipolar II depression were randomly assigned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment with lithium and sertraline (N=48). At each visit, mood was assessed using standardized rating scales. Rates of switch were compared, as were rates of treatment response and the presence and severity of treatment-emergent side effects. RESULTS: Twenty participants (14%) experienced a switch during the study period (hypomania, N=17; severe hypomania, N=3). Switch rates did not differ among the three treatment groups, even after accounting for dropout. No patient had a manic switch or was hospitalized for a switch. Most switches occurred within the first 5 weeks of treatment. The treatment response rate for the overall sample was 62.7% (N=89), without significant differences between groups after accounting for dropout. The lithium/sertraline combination group had a significantly higher overall dropout rate than the monotherapy groups but did not have an accelerated time to response. CONCLUSIONS: Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combination therapy were associated with similar switch and treatment response rates in participants with bipolar II depression. The dropout rate was higher in the lithium/sertraline combination treatment group, without any treatment acceleration advantage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and the economic burden of BDII is up to four times greater.425, 426”
In the citing paper
“While the use of antidepressants in BD remains controversial260, 426 and there have been no studies in older age BD; antidepressants are frequently used in this population (>40% of patients).666”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 987
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770
Self-citationPrien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Post, R. M., Denicoff, K. D., Leverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T. M., Rush, A. J., Keck, P. E., McElroy, S. L., Luckenbaugh, D. A., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0610 · Cited by 418
Self-citation
Research works printed but not linked: 2
- Sachs GS, 2000, Postgrad Med, 1
- Dunner DL, 1976, Biol Psychiatry, 11, 31
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationMcIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Fountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Antidepressants in bipolar depression: An enduring controversy
Gitlin, M. J. (2018) · International Journal of Bipolar Disorders · doi:10.1186/s40345-018-0133-9 · Cited by 116
Self-citationFornaro, M., Anastasia, A., Novello, S., Fusco, A., Solmi, M., Monaco, F., Veronese, N., De Berardis, D., & de Bartolomeis, A. (2018) · Bipolar Disorders · doi:10.1111/bdi.12612 · Cited by 93
“…limit limit Z–value P–value weight Altshuler et al. (2009) 0.157 0.093 0.251 –5.575 .000 2.13 Altshuler et al. (1995) 0.242 0.100 0.478 –2.121 .034 4.28 Altshuler et al. (2017) 0.232 0.144 0.353 –3.977 .000 6.47 Amstedam et al. (2005) 0.270 0.168 0.404 –3.215 .001 8.35 Amsterdam et al. (2004)…”
InfluentialGard, D. E., Pleet, M. M., Bradley, E. R., Penn, A. D., Gallenstein, M. L., Riley, L. S., DellaCrosse, M., Garfinkle, E. M., Michalak, E. E., & Woolley, J. D. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100240 · Cited by 36
Mixed features in major depressive disorder: diagnoses and treatments
Suppes, T. M., & Ostacher, M. J. (2017) · CNS Spectrums · doi:10.1017/s1092852917000256 · Cited by 39
Self-citationBeaupre, L. M., Tiwari, A. K., Gonçalves, V. F., Lisoway, A. J., Harripaul, R., Müller, D. J., Zai, C. C. H., & Kennedy, J. L. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001186 · Cited by 33
“In addition, this association may be influenced by age or whether the patients were experiencing BD-I or BD-II.(22,39) Speculation and further research would need to be performed to determine this.”
BackgroundLithium in the treatment of acute bipolar depression: A systematic review and meta-analysis
Rakofsky, J. J., Lucido, M. J., & Dunlop, B. W. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.058 · Cited by 34
Lithium, the gold standard drug for bipolar disorder: analysis of current clinical studies
Airainer, M., & Seifert, R. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03210-8 · Cited by 39
“There was no difference in the rates of mood change from depression to mania between sertraline and lithium (Altshuler et al. 2017).”
Oliva, V., Prisco, M. D., Spina, E. L., Paolucci, S., Fico, G., Anmella, G., Hidalgo‐Mazzei, D., Murru, A., Pompili, M., Fornaro, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103413 · Cited by 29
“47–50 Finally, the results of our post-hoc analyses, including classifications based on mechanisms of action and the NbN-3 system, should be interpreted with caution as they were not based on predefined hypotheses.”
Hu, Y., Zhang, H., Wang, H., Wang, C., Kung, S., & Li, C. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114468 · Cited by 27
Shim, I. H., Woo, Y. S., Kim, M.-D., & Bahk, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112406 · Cited by 26
“, 2017 [45] 142 (BP II) 16 Sertraline >100 vs.”
Treatment of anxiety disorders in patients with comorbid bipolar disorder
Ott, C. A. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.11.256 · Cited by 24
“Switch rates during a study of acute treatment comparing lithium monotherapy (n1⁄449), sertraline monotherapy (n1⁄4 45), and the combination (n1⁄448) were estimated to be approximately 14%, with no difference between the treatment arms.(25) Two studies focused on evaluating the correlates and rates of switch using a s…”
BackgroundEvaluating the efficacy and safety of antidepressants in patients with bipolar disorder
Cheniaux, E., & Nardi, A. E. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1651291 · Cited by 26
“[60] found no difference between sertraline, sertraline/lithium combination and lithium monotherapy in a sample of depressed bipolar type II patients.”
BackgroundResultInfluentialWang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 23
Byatt, N., Cox, L., Simas, T. A. M., Kini, N., Biebel, K., Sankaran, P., Swartz, H. A., & Weinreb, L. (2018) · Archives of Women s Mental Health · doi:10.1007/s00737-018-0825-2 · Cited by 22
“Use of antidepressant monotherapy in bipolar disorder, type II has more supporting evidence (Amsterdam and Shults 2010; Amsterdam et al. 2010) with lower risk of switching in bipolar disorder, type II relative to type I (Altshuler et al. 2006, 2017).”
BackgroundKelly, T. (2019) · Bipolar Disorders · doi:10.1111/bdi.12753 · Cited by 21
Park, J. H., Núñez, N. A., Gardea‐Resendez, M., Gerberi, D., Breitinger, S. A., Veldić, M., Frye, M. A., & Singh, B. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4433 · Cited by 16
The Use of Antidepressants in Bipolar Depression
Beyer, J. L. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_155 · Cited by 13
Antidepressants in Bipolar Depression: An Enduring Controversy
Gitlin, M. J. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17306 · Cited by 12
Self-citationAntidepressants have complex associations with longitudinal depressive burden in bipolar disorder
Hooshmand, F., Do, D., Shah, S., Gershon, A., Park, D. Y., Yuen, L. D., Dell’Osso, B. M., Wang, P. W., Miller, S., & Ketter, T. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.074 · Cited by 9
Amsterdam, J. D., & Xu, C. (2023) · Bipolar Disorders · doi:10.1111/bdi.13378 · Cited by 9
“Several controlled clinical trials of bipolar II depression 4,16,17 have shown good effectiveness of SSRI monotherapy with a low propensity for manic induction.”
BackgroundInfluentialAntidepressants in Bipolar II Depression: Yes and no
Pacchiarotti, I., & Verdolini, N. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.009 · Cited by 7
Neglected but not negligible aspects of antidepressants and their availability in bipolar depression
Terao, T. (2021) · Brain and Behavior · doi:10.1002/brb3.2308 · Cited by 7
“Furthermore, lithium monotherapy, sertraline monotherapy, and lithium/sertraline combination therapy were associated with similar switch and treatment response rates in participants with bipolar II depression (Altshuler et al., 2017).”
ResultGoldberg, J. F., Swartz, H. A., McIntyre, R. S., Mago, R., Malhi, G. S., Jha, M. K., Berk, M., Kasper, S. F., Freeman, M. P., Gitlin, M. J., et al. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10580 · Cited by 6
“…bipolar type 1 versus type 2 disorder may also be especially relevant for antidepressants, where some studies suggest a low risk for mood destabilisation, 28,29 and comparable 30 or even higher 30 acute antidepressant efficacy, even as monotherapy, than seen with mood stabilisers such as lithium.”
Self-citationSpelber, D., Almeida, J., & Nemeroff, C. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00019-0 · Cited by 5
Psychopharmacology and Experimental Therapeutics for Bipolar Depression
Jha, M. K., & Murrough, J. W. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190009 · Cited by 6
Unmet Needs in Psychiatry: Bipolar Depression
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-42637-8_4 · Cited by 8
Determining Patient Candidacy for Antidepressant Use in Bipolar Disorder
Goldberg, J. F. (2019) · Psychiatric Annals · doi:10.3928/00485713-20190807-03 · Cited by 6
Design limitations to bipolar II treatment efficacy studies: A challenge and a revisionist strategy
Parker, G. B., & Tavella, G. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.072 · Cited by 3
Shafiee, A., Moltazemi, H., Amini, M. J., Gargari, O. K., Safari, F., Abhari, F. S., Jafarabady, K., & Bakhtiyari, M. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103839 · Cited by 5
Rosenblat, J. D., & McIntyre, R. S. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108333252.031 · Cited by 3
Stimulants in Bipolar Depression: Risks and Benefits
Núñez, N. A., Salgado, M. F., & Frye, M. A. (2023) · Psychiatric Annals · doi:10.3928/00485713-20230201-01 · Cited by 2
Fakhri, A., Asadi, K., Pakseresht, S., Norouzi, S., & Rostami, H. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1258_22 · Cited by 3
“Journal of Family Medicine and Primary Care 443 Volume 12 : Issue 3 : March 2023 clear evidence that these drugs are appropriate for some BD patients, and in particular their safety for BD‐II depression.[16,20]”
BackgroundChen, Y., Yao, Y., Wu, C., Li, H., Zhang, M., & Peng, Z. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70143 · Cited by 2
Shafiq, S., Ronksley, P. E., Elliott, M. J., Bulloch, A. G. M., & Patten, S. B. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251355643 · Cited by 2
“2,18 – 21 However, a crucial caveat exists: these recommendations emphasize the use of antidepressants only in patients with “ pure depression ” and not those with a history of antidepressant-induced hypomania or mixed symptoms.”
Chapter 4. Psychiatric and Medical Comorbidities With Bipolar II Disorder
Rosenblat, J. D., Ostacher, M. J., & McIntyre, R. S. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379224.lg04 · Cited by 1
Lin, J., Liu, H., Wang, Z., Wu, C., Li, Y., Zhou, J., Xu, G., Pan, M., Chen, Z., Li, W., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.096 · Cited by 1
Antidepressants in Bipolar Depression: Still Controversial After All These Years
Mansur, R. B. (2023) · Psychiatric Annals · doi:10.3928/00485713-20230119-02 · Cited by 1
Landén, M., & Viktorin, A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17050488r
Mit welcher Strategie ist das Risiko für einen Switch in eine Hypomanie am geringsten?
Müller, E. (2018) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-018-2464-6
Miller, S., Ostacher, M. J., & Suppes, T. M. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371501.lr11
Self-citationCurrent and Future Vistas in Bipolar Disorder
Tamura, J. K., & McIntyre, R. S. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00202-9
Guidelines on Mood Stabilizers
Gfesser, J., & Kittel‐Schneider, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_117-1
Ahearn, E. P., Chen, P., & Sajatovic, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00031-4 · Cited by 3
Musetti, L., Tundo, A., Cambiali, E., Grande, C. D., de Filippis, R., Franceschini, C., Proietti, L., Betrò, S., Marazziti, D., & Dell’Osso, L. (2021) · CNS Spectrums · doi:10.1017/s109285292100078x
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg002
Cosgrove, V. E., Allende, S., Gwizdowski, I. S., Fischer, E. G., Ostacher, M. J., & Suppes, T. M. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00252-w
“A growing body of evidence suggests negligible overall improved outcomes for combination therapies, indicating that the question of monotherapy versus combination therapy remains highly relevant (Nierenberg et al. 2013; Altshuler et al. 2017; Geddes et al. 2011).”
BackgroundSelf-citationStage and symptoms of bipolar disorders
Bereda, G. (2022) · Insights on the Depression and Anxiety · doi:10.29328/journal.ida.1001030 · Cited by 1
Mood Stabilisers in the Treatment of Bipolar II Disorder
Bond, D. J., Hadjipavlou, G., & Yatham, L. N. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108333252.013
The Role of Antidepressants in Managing Bipolar II Disorder
Goldberg, J. F. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108333252.012
Chapter 11. Bipolar and Related Disorders
Miller, S., Ostacher, M. J., & Suppes, T. M. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980.lr11
Self-citation(2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.1748correction
Guidelines on Mood Stabilizers
Gfesser, J., & Kittel‐Schneider, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_117
Meyer, J. M., & Stahl, S. M. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009225069.004
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd05
Chapter 8. Mood Stabilizers and Antipsychotic Medications in Bipolar II Disorder
Solé, E., Garriga, M., & Vieta, E. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379224.lg08
Chapter 9. Antidepressant Medications in Bipolar II Disorder
McElroy, S. L., & Israel, A. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379224.lg09 · Cited by 1
Self-citationChapter 12. Reproductive-Age Women With Bipolar II Disorder
Moses‐Kolko, E. L., Clark, C. T., DeBrunner, S. A., & Wisner, K. L. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379224.lg12 · Cited by 1
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg002.pub2
Antidepressant Remission and Manic Switch in Bipolar Depression: A Propensity Score Analysis
Vöhringer, P. A., Barroilhet, S. A., Palma, B. A., & Perlis, R. H. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13822 · Cited by 4
Mood Stabilizers Are the First Line of Treatment for Bipolar Disorder
Shah, S. R., Ibrahim, K., Sadah, A., & El‐Mallakh, R. S. (2026) · Southern Medical Journal · doi:10.14423/smj.0000000000001959
Park, K. J., Kim, Y. W., Jung, E., Kim, J. Y., & Kim, H. (2026) · Bipolar Disorders · doi:10.1111/bdi.70125
“Although some research has explored the potential of antidepressant monotherapy in adults [38], further research is necessary to establish the safe and effective use of antidepressants in children and adolescents with bipolar spectrum disorders.”
Delvecchio, G., Videtta, G., Squarcina, L., Consoli, L. D., Siri, F. M., Ferro, A., Schiena, G., Barone, Y., Callari, A., Nosari, G., et al. (2026) · Bipolar Disorders · doi:10.1111/bdi.70131
“However, the effects of antidepressants combined with mood stabilizers on phase switching would appear to be less impact-ful than one might think [6], even considering a mood transition from depression to hypomania rather than mania [7].”
Fornaro, M., Lorenzo, C. D., Oliva, V., Prisco, M. D., & Vieta, E. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122160 · Cited by 4
Rozpoznawanie zaburzenia dwubiegunowego: od doświadczenia pacjenta do diagnozy klinicznej
Laskowski, L. (2026) · Analiza Egzystencjalna i Fenomoenologia Życia · doi:10.63867/aeif.19
Metadata
- Authors
- Altshuler, L. L., Sugar, C. A., McElroy, S. L., Calimlim, B., Gitlin, M., Keck, P. E., Aquino-Elias, A., Martens, B. E., Fischer, E. G., English, T. L., Roach, J., & Suppes, T.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2017-03-01
- Volume
- 174
- Issue
- 3
- Pages
- 266-276
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2584979231
- Cited by
- 68
- References
- 43
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 12 · 2018: 12 · 2017: 4
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Keywords
- bipolar II depression, lithium monotherapy, acute phase treatment, treatment response, dropout, hypomania
- MeSH terms
- Adult, Affect, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Patient Dropouts, Psychiatric Status Rating Scales, Risk, Lithium Carbonate, Treatment Outcome, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.